A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 06 Dec 2021 Status changed from active, no longer recruiting to completed.
- 27 Aug 2021 Planned End Date changed from 28 Jul 2021 to 28 Oct 2021.
- 19 May 2021 Planned End Date changed from 31 Dec 2021 to 28 Jul 2021.